♦ CVS Health. Advanced Control Choice Formulary™

April 2025 Updates

| Removals | Additions |
|----------|-----------|
| 3 | 2 |

Formulary Removals

| Drug Class | Removed Product(s) | Formulary Options |
|----------------------------------------------|--------------------|-------------------------------------------------|
| Antineoplastic Agents, Kinase Inhibitors* | COTELLIC | MEKINIST, MEKTOVI |
| | SPRYCEL** | dasatinib, imatinib mesylate, BOSULIF, SCEMBLIX |
| | ZELBORAF | BRAFTOVI, TAFINLAR |

Formulary Additions

| Drug Class | Product(s) Added |
|----------------------------------------------|-------------------------------------|
| Antineoplastic Agents, Kinase Inhibitors* | MEKINIST TABLETS, TAFINLAR CAPSULES |

Indication-Based Strategy Updates

| Drug Class | Target Product(s) | Formulary Options |
|-----------------------------------------------------------------------|-------------------|------------------------------------------------------------|
| Autoimmune Agents, Self-Administered, Hidradenitis Suppurativa† | AMJEVITA | ADALIMUMAB-ADAZ, COSENTYX SUBCUTANEOUS, HUMIRA, HYRIMOZ |

*Class has existing formulary exclusions **Multi-source Brand Product [†]New Indication-Based category. This chart contains references to brandname prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or one of its affiliates. Information listed is current as of January 31, 2025 and subject to change.